StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Moderna (MRNA) Stock Gains While Street Analysts Discuss What Comes Next Following Early Flu Vaccine Data
December 13, 2021 7:50 AM
Analysts continue to discuss early data for Moderna’s (NASDAQ: MRNA) flu vaccine, released by the company last week.Morgan Stanley analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Moderna (MRNA) and Australia Collaborate to Bring mRNA Manufacturing to Australia
December 14, 2021 5:50 AM
Moderna's (MRNA) COVID-19 Vaccine Manufactured in Korea by Samsung Granted Marketing Authorization from Ministry of Food and Drug Safety of Korea
December 14, 2021 5:46 AM
Moderna (MRNA) Stock Down 11% on Likely Disappointing Flu Vaccine Data, Seen as 'Undifferentiated' by Morgan Stanley
December 10, 2021 9:51 AM
